~~<i id='8FDBE9FE3F'><strike id='8FDBE9FE3F'><tt id='8FDBE9FE3F'><pre id='8FDBE9FE3F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

knowledge

author：hotspot 2025-09-06 03:57:49 - browse：5

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Questions and answers about ramping up H5N1 bird flu vaccine

hotspot

focus

hotspot

Wikipedia

focus

hotspot

MattRourke/APNiacin,orvitaminB3,haslongbeenaU.S.publichealthdarlingtothepointthatitisadded,bylaw,toc

WSS

Elevance, SCAN deals highlight health insurer acquisition scrutiny

ASCO eve: Let’s set the table for this year's meeting

ASCO eve: Let’s set the table for this year's meeting

Medicare Advantage enrollment hits roughly 33.4 million

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Scrutiny of post

entertainment

knowledge

hotspot

Alkermes shareholders re

As a primary care physician, here's how I hope to partner with AI

Bright Health sells Medicare Advantage business to Molina

Weight loss drugs aren’t covered by Obamacare. That may change

Malaria cases in Florida and Texas: Here’s what you need to know

FDA poised to publish guidelines for clinical trial diversity

At least 13 dead in Texas as scorching temps continue

For longer

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Ukraine seeks to reclaim its role as a hub for clinical trials

focus

Listen: More tumult at BIO & coercive care for sickle cell patients

Measles policy set amid Florida outbreak alarms vaccine proponents

New CMS data security rules will hurt Medicare, Medicaid research

Weight loss drugs aren’t covered by Obamacare. That may change

Digital health: a case of mistaken identity

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

hotspot

Wikipedia

focus

hotspot